Adverum Biotechnologies, Inc.
11
2
5
6
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
0.0%
0 terminated/withdrawn out of 11 trials
100.0%
+13.5% vs industry average
18%
2 trials in Phase 3/4
50%
3 of 6 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS)
Role: lead
Long-term Study of ADVM-022 in Neovascular (Wet) AMD [OPTIC-EXT]
Role: lead
Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular Degeneration
Role: lead
Safety and Efficacy of ADVM-022 in Treatment-Experienced Patients With Neovascular Age-related Macular Degeneration [LUNA]
Role: lead
ADVM-022 Intravitreal Gene Therapy for DME
Role: lead
Long-Term Follow-up Study of ADVM-022 in DME (INFINITY-EXT)
Role: lead
Long-Term Follow-up Study of ADVM-043
Role: lead
Safety Dose Finding Study of ADVM-043 Gene Therapy to Treat Alpha-1 Antitrypsin (A1AT) Deficiency
Role: lead
ADVM-022 Intravitreal Gene Therapy for Wet AMD
Role: lead
A Study to Characterize the Cardiac Phenotype of Individuals With Friedreich's Ataxia (CARFA Study)
Role: lead
Safety and Efficacy Study of rAAV.sFlt-1 in Patients With Exudative Age-Related Macular Degeneration
Role: collaborator
All 11 trials loaded